News
FATE
2.110
-3.65%
-0.080
BofA Securities: Which small cap non-earner stocks to avoid
Seeking Alpha · 3d ago
Weekly Report: what happened at FATE last week (0911-0915)?
Weekly Report · 5d ago
Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength?
NASDAQ · 09/15 10:01
FATE, MVST and PAYO are among after hour movers
Seeking Alpha · 09/13 21:07
Weekly Report: what happened at FATE last week (0904-0908)?
Weekly Report · 09/11 11:29
Cantor Fitzgerald Reiterates Fate Therapeutics (FATE) Neutral Recommendation
NASDAQ · 09/08 00:07
Analyst Ratings for Fate Therapeutics
Benzinga · 09/07 15:00
Cantor Fitzgerald Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Benzinga · 09/07 14:44
Weekly Report: what happened at FATE last week (0828-0901)?
Weekly Report · 09/05 04:30
Fate Therapeutic: Current report
Press release · 09/01 22:03
TRxADE HEALTH, ARS Pharmaceuticals, Aditxt among healthcare movers
Seeking Alpha · 09/01 14:00
MVIS, DHC and RUM are among after hour movers
Seeking Alpha · 08/28 21:17
Weekly Report: what happened at FATE last week (0821-0825)?
Weekly Report · 08/28 11:36
Fate Therapeutic: Statement of changes in beneficial ownership of securities
Press release · 08/21 21:04
Fate Therapeutic: Report of proposed sale of securities
Press release · 08/18 22:02
Truist Securities Reiterates Fate Therapeutics (FATE) Hold Recommendation
NASDAQ · 08/17 10:52
The Latest Analyst Ratings for Fate Therapeutics
Benzinga · 08/16 17:01
Truist Securities Reiterates Hold on Fate Therapeutics, Maintains $7 Price Target
Benzinga · 08/16 15:45
Fate Therapeutics: Not Now, Maybe Never?
Seeking Alpha · 08/16 13:05
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.